Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

被引:57
作者
Chandra, J
Hackbarth, J
Le, S
Loegering, D
Bone, N
Bruzek, LM
Narayanan, VL
Adjei, AA
Kay, NE
Tefferi, A
Karp, JE
Sausville, EA
Kaufmann, SH
机构
[1] Mayo Clin, Div Oncol Res, Dept Oncol, Rochester, MN 55901 USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN 55901 USA
[3] Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN USA
[4] NCI, Dev Therapeut Program, Div Canc Treatment & Diagnosis, Bethesda, MD 20892 USA
[5] Univ Maryland, Greenbaum Canc Ctr, Baltimore, MD 21201 USA
关键词
D O I
10.1182/blood-2003-02-0562
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adaphostin (NSC 680410), an analog of the tyrphostin AG957, was previously shown to induce Bcr/abl down-regulation followed by loss of clonogenic survival in chronic myelogenous leukemia (CML) cell lines and clinical samples. Adaphostin demonstrated selectivity for CML myeloid progenitors in vitro and remained active in K562 cells selected for imatinib mesylate resistance. In the present study, the mechanism of action of adaphostin was investigated in greater detail in vitro. Initial studies demonstrated that adaphostin induced apoptosis in a variety of Bcr/ abl(-) cells, including acute myelogenous leukemia (AML) blasts and cell lines as well as chronic lymphocytic leukemia (CLL) samples. Further study demonstrated that adaphostin caused intracellular peroxide production followed by DNA strand breaks and, in cells containing wild-type p53, a typical DNA damage response consisting of p53 phosphorylation and up-regulation. Importantly, the antioxidant N-acetylcysteine (NAC) blunted these events, whereas glutathione depletion with buthionine sulfoximine (BSO) augmented them. Collectively, these results not only outline a mechanism by which adaphostin can damage both myeloid and lymphoid leukemia cells, but also indicate that this novel agent might have a broader spectrum of activity than originally envisioned.
引用
收藏
页码:4512 / 4519
页数:8
相关论文
共 42 条
[1]   Cell cycle checkpoint signaling through the ATM and ATR kinases [J].
Abraham, RT .
GENES & DEVELOPMENT, 2001, 15 (17) :2177-2196
[2]   Glutathione therapy: From prodrugs to genes [J].
Anderson, ME ;
Luo, JL .
SEMINARS IN LIVER DISEASE, 1998, 18 (04) :415-424
[3]   In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines [J].
Avramis, IA ;
Christodoulopoulos, G ;
Suzuki, A ;
Lang, WE ;
Gonzalez-Gomez, I ;
McNamara, G ;
Sausville, EA ;
Avramis, VI .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 50 (06) :479-489
[4]   Effects of the tyrosine kinase inhibitor AG957 and an anti-Fas receptor antibody on CD34+ chronic myelogenous leukemia progenitor cells [J].
Carlo-Stella, C ;
Regazzi, E ;
Sammarelli, G ;
Colla, S ;
Garau, D ;
Gazit, A ;
Savoldo, B ;
Cilloni, D ;
Tabilio, A ;
Levitzki, A ;
Rizzoli, V .
BLOOD, 1999, 93 (11) :3973-3982
[5]  
Dorsey JF, 2000, CANCER RES, V60, P3127
[6]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[7]   Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].
Druker, BJ ;
Tamura, S ;
Buchdunger, E ;
Ohno, S ;
Segal, GM ;
Fanning, S ;
Zimmermann, J ;
Lydon, NB .
NATURE MEDICINE, 1996, 2 (05) :561-566
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]   Mechanisms of disease - The biology of chronic myeloid leukemia [J].
Faderl, S ;
Talpaz, M ;
Estrov, Z ;
O'Brien, S ;
Kurzrock, R ;
Kantarjian, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172
[10]   Inhibition of human caspases by peptide-based and macromolecular inhibitors [J].
Garcia-Calvo, M ;
Peterson, EP ;
Leiting, B ;
Ruel, R ;
Nicholson, DW ;
Thornberry, NA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (49) :32608-32613